ORTX on NASDAQ

Orchard Therapeutics

British gene therapy company founded in 20151

In its 2023 annual report the company says: “We are a global gene therapy company dedicated to transforming the lives of people affected by rare diseases through the development of innovative, potentially curative gene therapies.”52 It is headquartered in London, United Kingdom.1 It employed 180 people.1 Its revenue was $17.1 million.1 Its shares trade on NASDAQ under the symbol ORTX.1

Price unavailable

Last updated Oct 20, 2026.

Overview

2015Founded1

Compare with Alector (United States), Metagenomi Therapeutics, Inc. or LENZ Therapeutics, Inc., or pick any stock.

  • TickerORTX on NASDAQ1
  • Industrypharmaceutical industry1
  • HeadquartersLondon, United Kingdom1
  • Websitewww.orchard-tx.com
  • Incorporated inUnited Kingdom4
  • Business address245 Hammersmith Road, 3Rd Floor, London, X0 W6 8Pw4
  • Filer categoryNon-accelerated filer, Smaller reporting company4
  • Legal formOther3
  • LEI21380056R45ONMT94Z503
  • StatusInactive3
  • LEI statusRetired3
  • Registered address108 CANNON STREET, EC4N 6EU London, United Kingdom3
  • Registered withCompanies House, 114943813

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-561.0%Operating margin5
-665.0%Net margin5
1252.5%Revenue growth, 20225
-153.3%Return on equity5
0.23×Debt to equity5
-$82.5MFree cash flow5

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue4¢$6.8M
  • Research and development60¢$93.8M
  • Selling, general and admin32¢$49.1M
  • Interest2¢$3.1M
  • Income tax2¢$2.4M

Out of $22.7M in revenue.5 The company lost money this year.

Financial statements

Revenue67895$22.7M in 2022
0$10.0M$20.0M$30.0M2017: $0$020172018: $2.1M$2.1M20182019: $2.5M$2.5M2019+21%2020: $2.6M$2.6M2020+3%2021: $1.7M$1.7M2021−35%2022: $22.7M$22.7M2022+1253%
Operating income67895-$127.1M in 2022+562% since 2016
-$300.0M-$200.0M-$100.0M02016: -$19.2M-$19.2M20162017: -$38.5M-$38.5M2017+101%2018: -$235.0M-$235.0M2018+510%2019: -$172.9M-$172.9M2019−26%2020: -$157.0M-$157.0M2020−9%2021: -$140.4M-$140.4M2021−11%2022: -$127.1M-$127.1M2022−10%
Net income67895-$150.7M in 2022+689% since 2016
-$300.0M-$200.0M-$100.0M02016: -$19.1M-$19.1M20162017: -$39.7M-$39.7M2017+108%2018: -$230.5M-$230.5M2018+480%2019: -$163.4M-$163.4M2019−29%2020: -$152.0M-$152.0M2020−7%2021: -$144.6M-$144.6M2021−5%2022: -$150.7M-$150.7M2022+4%
Fiscal year2016201720182019202020212022
Revenue$06$2.1M7$2.5M8$2.6M9$1.7M5$22.7M5
Cost of revenue$422.0K7$805.0K8$857.0K9$226.0K5$6.8M5
Research and development$16.2M6$32.5M7$205.3M7$117.4M8$93.7M9$87.0M5$93.8M5
Selling, general and admin$3.0M6$6.0M7$31.4M7$57.2M8$65.0M9$54.9M5$49.1M5
Operating expenses$142.1M5$149.7M5
Operating income-$19.2M6-$38.5M7-$235.0M7-$172.9M8-$157.0M9-$140.4M5-$127.1M5
Interest$1.5M8$2.3M9$2.5M5$3.1M5
Income before tax-$143.8M5-$153.0M5
Income tax$20.0K6$53.0K7$970.0K7-$2.2M8-$731.0K9$828.0K5-$2.4M5
Net income-$19.1M6-$39.7M7-$230.5M7-$163.4M8-$152.0M9-$144.6M5-$150.7M5
Earnings per share-$1.175-$1.185
Earnings per share (diluted)-$1.175-$1.185
Shares (weighted, basic)124.0M shares5128.0M shares5
Shares (weighted, diluted)124.0M shares5128.0M shares5

Compare Orchard Therapeutics with another company

Corporate structure

Orchard Therapeutics sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Orchard Therapeutics

  • Blue Owl Capital Filed SC 13G/A on Orchard Therapeutics, latest Nov 14, 2024 (2 filings since Feb 14, 2024)
  • Deep Track Capital, LP Filed SC 13G/A on Orchard Therapeutics, latest Nov 14, 2024 (2 filings since Mar 20, 2023)
  • RA CAPITAL MANAGEMENT, L.P. Filed SC 13G/A on Orchard Therapeutics, latest Feb 14, 2024 (4 filings since Feb 14, 2022)
  • FMR LLC Filed SC 13G/A on Orchard Therapeutics, latest Feb 12, 2024 (3 filings since Feb 9, 2022)
  • Beryl Capital Management LLC Filed SC 13G/A on Orchard Therapeutics, latest Feb 8, 2024 (2 filings since Oct 16, 2023)
  • CHI Advisors LLC Filed SC 13G/A on Orchard Therapeutics, latest Feb 13, 2023 (2 filings since Feb 11, 2022)
  • James E. Flynn Filed SC 13G/A on Orchard Therapeutics, latest Feb 10, 2023 (2 filings since Feb 11, 2022)
  • Zentree Investments Ltd Filed SC 13G/A on Orchard Therapeutics, latest Feb 9, 2023 (3 filings since Sep 9, 2022)
  • Artisan Partners Limited Partnership Filed SC 13G/A on Orchard Therapeutics, latest May 9, 2022 (2 filings since Feb 4, 2022)
  • Orchard Therapeutics London, United Kingdom

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Orchard Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$14.9M5 Dec 31, 2022$10.9M5 Dec 31, 2021+36.7%
Accumulated depreciation$6.8M5 Dec 31, 2022$6.2M5 Dec 31, 2021+10.3%
Property and equipment, net$8.1M5 Dec 31, 2022$4.8M5 Dec 31, 2021+70.7%
Operating-lease assets (leased space)$22.8M5 Dec 31, 2022$24.3M5 Dec 31, 2021−6.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$68.4M5 Dec 31, 2022$55.9M5 Dec 31, 2021+22.4%
Debt securities available for sale$101.2M5 Dec 31, 2022$184.7M5 Dec 31, 2021−45.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$3.6M5 Dec 31, 2022$4.1M5 Dec 31, 2021−14.2%
Finite-lived intangibles, gross$4.1M5 Dec 31, 2022$4.3M5 Dec 31, 2021−6.0%
Accumulated amortization$509.0K5 Dec 31, 2022$180.0K5 Dec 31, 2021+182.8%
Finite-lived intangibles, net$3.6M5 Dec 31, 2022$4.1M5 Dec 31, 2021−14.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$3.4M5 Dec 31, 2022$2.0M5 Dec 31, 2021+68.7%

Leadership

Who has led Orchard Therapeutics, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Bobby Gaspar2020–2024
20202025
Board members and other officers (15)

Former names

  • Orchard Rx LtdAug 6, 2018 to Oct 26, 20184

Timeline

  1. Jan 24, 20248-K Ended a material agreement; Completed an acquisition or sale; Listing notice or transfer25
  2. Jan 22, 20248-K Other events26
  3. Dec 19, 20238-K Shareholder vote; Regulation FD disclosure; Other events27
  4. Dec 8, 20238-K Other events28
  5. Nov 30, 20238-K Other events29
  6. Nov 21, 20238-K Other events30
  7. Nov 13, 20238-K Results of operations31
  8. Oct 26, 20238-K Other events32
  9. Oct 5, 20238-K Entered a material agreement; Executive or director change; Regulation FD disclosure33
  10. Sep 18, 20238-K Other events34
  11. Aug 3, 20238-K Results of operations; Regulation FD disclosure35
  12. Jun 26, 20238-K Unregistered sale of shares; Regulation FD disclosure36
  13. Apr 3, 2020New chief executive Bobby Gaspar becomes CEO12
  14. 2015Founded Founded1

Calendar

When it reported results

  1. Nov 13, 2023Reported quarterly or annual results31
  2. Aug 3, 2023Reported quarterly or annual results35
  3. May 15, 2023Reported quarterly or annual results37
  4. Mar 6, 2023Reported quarterly or annual results38
  5. Nov 14, 2022Reported quarterly or annual results39
  6. Aug 4, 2022Reported quarterly or annual results40
  7. May 12, 2022Reported quarterly or annual results41
  8. Mar 30, 2022Reported quarterly or annual results42

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

142 filings to the SEC since October 2021: 2 annual reports, 7 quarterly reports, 37 major events, 33 insider forms, 22 large holders, 1 private raises, 40 other. The latest 20:

  1. Nov 14, 2024SC 13G/A EDGAR
  2. Nov 14, 2024SC 13G/A EDGAR
  3. Feb 14, 2024SC 13G EDGAR
  4. Feb 14, 2024SC 13G/A EDGAR
  5. Feb 12, 2024SC 13G/A EDGAR
  6. Feb 9, 2024SC 13G/A EDGAR
  7. Feb 8, 2024SC 13G/A EDGAR
  8. Feb 5, 202415-12G EDGAR
  9. Jan 30, 2024EFFECT EDGAR
  10. Jan 30, 2024EFFECT EDGAR
  11. Jan 24, 2024S-8 POS EDGAR
  12. Jan 24, 2024S-8 POS EDGAR
  13. Jan 24, 2024S-8 POS EDGAR
  14. Jan 24, 2024S-8 POS EDGAR
  15. Jan 24, 2024S-8 POS EDGAR
  16. Jan 24, 2024S-8 POS EDGAR
  17. Jan 24, 2024POS AM EDGAR
  18. Jan 24, 2024POS AM EDGAR
  19. Jan 24, 20248-K EDGAR
  20. Jan 24, 20244 EDGAR

The 142 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 2 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 1, 2022Gaspar BobbyChief Executive OfficerBuy15,000$0.74$11.1KForm 4
Apr 1, 2022THOMAS FRANK ESee RemarksBuy10,000$0.75$7.5KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Mar 10, 2023Raised $34 million in a private offering of equity Form D: 7 investors so far Form D

SEC filer profile

How Orchard Therapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGAROrchard Therapeutics plc2
  • CIK0001748907
  • Filer statusNon-accelerated filer<br>smaller reporting company2
  • Incorporated inUnited Kingdom2
  • Fiscal year endsDecember 312
  • Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)2
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance2
  • Business address245 Hammersmith Road, 3Rd Floor, London, X0 W6 8PW2
  • Phone011-44-0-203-38467002
  • Shares outstanding227,610,439 as of Nov 9, 202311
  • Public float$74.0M as of Jun 30, 20225
  • On EDGAR sinceAug 6, 20182
  • Filings339 in all: 8-K (78), 4 (65), 6-K (33), SC 13G/A (29), 3 (14), SC 13G (14), 10-Q (12), CORRESP (10)2
    All 45 form types

    EFFECT (7), UPLOAD (7), S-8 (6), S-8 POS (6), DEFA14A (5), DEFA14C (5), 10-K (4), DEF 14A (4), PRE 14A (3), 424B4 (2), D (2), DRS (2), DRS/A (2), F-1 (2), F-1/A (2), POS AM (2), POSASR (2), S-3 (2), 15-12G (1), 20-F (1), 20-F/A (1), 25-NSE (1), 424B3 (1), 424B5 (1), 8-A12B (1), ARS (1), CERT (1), CT ORDER (1), DEFM14A (1), DRSLTR (1), F-1MEF (1), F-3ASR (1), F-6 (1), F-6 POS (1), F-6/A (1), PREM14A (1), S-3ASR (1)

  • Latest filingsAnnual report (10-K) Mar 14, 2023
    Quarterly report (10-Q) Nov 13, 2023
    Proxy statement (DEF 14A) Apr 27, 2023
    Latest 8-K (8-K) Jan 24, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
    SEC EDGAROther events
  27. 27
  28. 28
    SEC EDGAROther events
  29. 29
    SEC EDGAROther events
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
    SEC EDGAROther events
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52